Calidi Biotherapeutics Inc. Reports Q2 2025 Financial Results and Advances in Oncology Therapies

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company focused on developing targeted therapies for metastatic diseases, announced its financial results for the second quarter of 2025. The company reported a net loss of $5.7 million, or $1.99 per share, an improvement from the $7.4 million loss, or $16.75 per share, recorded in the same quarter the previous year. Research and development expenses increased to $2.6 million from $2.2 million, while general and administrative expenses decreased to $3.1 million from $3.6 million. Calidi concluded the quarter with $5.3 million in cash and $0.1 million in restricted cash.

Among the quarter's highlights, Calidi shared new preclinical data on CLD-401 from its proprietary RedTail platform. The data demonstrated enhanced efficacy through the systemic delivery of an IL15 superagonist and immune-evasion via engineered CD55 expression. Additionally, the company raised $4.6 million through a warrant inducement offering, bringing the total gross proceeds for 2025 to $15.7 million. A significant milestone was achieved with the FDA granting Fast Track Designation for CLD-201 in treating soft tissue sarcoma, alongside an open Investigational New Drug (IND) application for a Phase 1 trial.

For more detailed information, the full press release can be accessed here. Calidi Biotherapeutics continues to pioneer in the immuno-oncology field, leveraging its Redtail platform to develop therapies aimed at delivering genetic medicines to metastatic disease sites. The platform's engineered enveloped oncolytic virus is designed for systemic delivery, targeting metastatic sites while evading immune clearance to enhance treatment efficacy.

The company's lead candidate from the Redtail platform is currently in IND-enabling studies, targeting non-small cell lung cancer, ovarian cancer, and other tumors with high unmet medical needs. Calidi is also advancing its clinical-stage protected virotherapies for intratumoral and localized administration, focusing on injectable cancer indications. Investors and interested parties can find the latest news and updates on Calidi Biotherapeutics in the company's newsroom here.